Versions - Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance

    Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance by Andrew F. Shorr, Mark E. Jones, Silke Friedmann, Daniel Ionescu, Mikael Saulay, Jennifer I. Smart, Marc Engelhardt

    Published 2025-01-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.

    Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance. by Andrew F Shorr, Mark E Jones, Silke Friedmann, Daniel Ionescu, Mikael Saulay, Jennifer I Smart, Marc Engelhardt

    Published 2025-01-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: